159878-00-9Relevant articles and documents
Development of a continuous process for the industrial generation of diazomethane
Proctor, Lee D.,Warr, Antony J.
, p. 884 - 892 (2002)
The development of a safe process for the industrial generation of diazomethane is described. Diazomethane is produced and consumed in a continuous process capable of generating between 50 and 60 tonnes per year whilst the maximum inventory is maintained
Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease
Kaldor, Stephen W.,Kalish, Vincent J.,Davies II, Jay F.,Shetty, Bhasker V.,Fritz, James E.,Appelt, Krzysztof,Burgess, Jeffrey A.,Campanale, Kristina M.,Chirgadze, Nickolay Y.,Clawson, David K.,Dressman, Bruce A.,Hatch, Steven D.,Khalil, Deborah A.,Kosa, Maha B.,Lubbehusen, Penny P.,Muesing, Mark A.,Patick, Amy K.,Reich, Siegfried H.,Su, Kenneth S.,Tatlock, John H.
, p. 3979 - 3985 (2007/10/03)
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor